Response and outcome according to the randomization group
| . | R-ACVBP (n = 109) . | R-CHOP14 (n = 102) . | All (n = 211) . | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N . | % . | 4-year PFS (95% CI) . | P . | 4-year OS (95% CI) . | P . | N . | % . | 4-year PFS (95% CI) . | P . | 4-year OS (95% CI) . | P . | N . | % . | 4-year PFS (95% CI) . | P . | 4-year OS (95% CI) . | P . | |
| Response (IWG 2007) after 4 cycles of R- chemo | ||||||||||||||||||
| Complete response | 51 | 47 | 82.1 (68.4-90.1) | .025 | 94.1 (82.9-98.1) | .12 | 40 | 39 | 82.2 (66.2-91.1) | <.0001 | 87.2 (71.9-94.5) | .0001 | 91 | 43 | 82.2 (72.5-88.7) | <.0001 | 91.1 (83-95.5) | .0045 |
| Partial response | 47 | 43 | 74.3 (59.2-84.5) | 80.8 (66.3-89.5) | 52 | 51 | 78.8 (65.1-87.7) | 82.9 (64.4-92.4) | 99 | 47 | 76.7 (67.1-83.9) | 81.8 (70.7-89) | ||||||
| Stable disease | 3 | 3 | 40 (5.2-75.3) | 80 (20.4-96.9) | 1 | 1 | 0 | 40 (5.2-75.3) | 4 | 2 | 20 (3.1-47.5) | 60 (25.3-82.7) | ||||||
| Progressive disease | 2 | 2 | 5 | 5 | 7 | 3 | ||||||||||||
| Metabolic response | ||||||||||||||||||
| PET4− | 58 | 53 | 80.8 (68-88.9) | 93.1 (82.7-97.4) | 42 | 41 | 78.2 (62.3-88) | 85.4 (70.3-93.1) | 100 | 47 | 79.8 (79.4-86.4) | 88.9 (82.1-94.4) | ||||||
| PET2−/PET4− | 28 | 26 | 78.6 (58.4-89.8) | .71 | 90 (72.1-96.7) | .35 | 24 | 24 | 70.8 (48.4-84.9) | .24 | 83.3 (61.5-93.4) | .69 | 52 | 24 | 75 (60.9-84.6) | .26 | 89.6 (85-92.2) | .21 |
| PET2+/PET4− | 30 | 28 | 82 (63.6-92.5) | 96.4 (77.2-99.5) | 18 | 18 | 88.5 (61.4-97) | 88.2 (60.6-96.9) | 48 | 23 | 85 (71.1-92.6) | 90.4 (81-95.1) | ||||||
| PET4+ | 45 | 41 | 70.8 (55.1-81.9) | .17* | 79.9 (65-89) | .054* | 55 | 54 | 74.5 (60.8-84.1) | .51* | 80.1 (62.4-90.1) | .68* | 100 | 47 | 72.9 (63.1-80.6) | .16* | 80 (69-87.5) | .08* |
| Premature withdrawal | 6 | 6 | 5 | 5 | 11 | 5 | ||||||||||||
| All | 109 | 75 (65.6-82.1) | 85.3 (77.1-90.7) | 102 | 74.2 (64.4-81.6) | 80.7 (70.4-87.7) | 211 | 100 | 74.6 (68.1-80) | 83 (76.8-87.7) | ||||||||
| . | R-ACVBP (n = 109) . | R-CHOP14 (n = 102) . | All (n = 211) . | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N . | % . | 4-year PFS (95% CI) . | P . | 4-year OS (95% CI) . | P . | N . | % . | 4-year PFS (95% CI) . | P . | 4-year OS (95% CI) . | P . | N . | % . | 4-year PFS (95% CI) . | P . | 4-year OS (95% CI) . | P . | |
| Response (IWG 2007) after 4 cycles of R- chemo | ||||||||||||||||||
| Complete response | 51 | 47 | 82.1 (68.4-90.1) | .025 | 94.1 (82.9-98.1) | .12 | 40 | 39 | 82.2 (66.2-91.1) | <.0001 | 87.2 (71.9-94.5) | .0001 | 91 | 43 | 82.2 (72.5-88.7) | <.0001 | 91.1 (83-95.5) | .0045 |
| Partial response | 47 | 43 | 74.3 (59.2-84.5) | 80.8 (66.3-89.5) | 52 | 51 | 78.8 (65.1-87.7) | 82.9 (64.4-92.4) | 99 | 47 | 76.7 (67.1-83.9) | 81.8 (70.7-89) | ||||||
| Stable disease | 3 | 3 | 40 (5.2-75.3) | 80 (20.4-96.9) | 1 | 1 | 0 | 40 (5.2-75.3) | 4 | 2 | 20 (3.1-47.5) | 60 (25.3-82.7) | ||||||
| Progressive disease | 2 | 2 | 5 | 5 | 7 | 3 | ||||||||||||
| Metabolic response | ||||||||||||||||||
| PET4− | 58 | 53 | 80.8 (68-88.9) | 93.1 (82.7-97.4) | 42 | 41 | 78.2 (62.3-88) | 85.4 (70.3-93.1) | 100 | 47 | 79.8 (79.4-86.4) | 88.9 (82.1-94.4) | ||||||
| PET2−/PET4− | 28 | 26 | 78.6 (58.4-89.8) | .71 | 90 (72.1-96.7) | .35 | 24 | 24 | 70.8 (48.4-84.9) | .24 | 83.3 (61.5-93.4) | .69 | 52 | 24 | 75 (60.9-84.6) | .26 | 89.6 (85-92.2) | .21 |
| PET2+/PET4− | 30 | 28 | 82 (63.6-92.5) | 96.4 (77.2-99.5) | 18 | 18 | 88.5 (61.4-97) | 88.2 (60.6-96.9) | 48 | 23 | 85 (71.1-92.6) | 90.4 (81-95.1) | ||||||
| PET4+ | 45 | 41 | 70.8 (55.1-81.9) | .17* | 79.9 (65-89) | .054* | 55 | 54 | 74.5 (60.8-84.1) | .51* | 80.1 (62.4-90.1) | .68* | 100 | 47 | 72.9 (63.1-80.6) | .16* | 80 (69-87.5) | .08* |
| Premature withdrawal | 6 | 6 | 5 | 5 | 11 | 5 | ||||||||||||
| All | 109 | 75 (65.6-82.1) | 85.3 (77.1-90.7) | 102 | 74.2 (64.4-81.6) | 80.7 (70.4-87.7) | 211 | 100 | 74.6 (68.1-80) | 83 (76.8-87.7) | ||||||||
PET4+ vs PET4−.